IsoPlexis Corporation ( ISO) Stock. Should you Buy or Sell? $ 2.18
0.06 (2.68 %)
IsoPlexis Corporation Analysis
Updated on 10-09-2022| Symbol | ISO |
| Price | $2.18 |
| Beta | 0.000 |
| Volume Avg. | $86.17 thousand |
| Market Cap | $85.9 M |
| 52 Week Range | $1.62 - $16.95 |
IsoPlexis Corporation opened the day at $2.18 which is +'2.68 % on yesterday's close. IsoPlexis Corporation has a 52 week high of $16.95 and 52 week low of $1.62, which is a difference of $15.33. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $85.9 M and total net profit is $17258 which means the company is trading at 4977.67 times profit to market capitalization. Theoretically, if you were to buy IsoPlexis Corporation for $85.9 M, it would take 15 years to get your money back. IsoPlexis Corporation are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
IsoPlexis Corporation Stock Forecast - Is IsoPlexis Corporation a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Buy | |
| PE Score | Sell | |
| PB Score | Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | 0.222 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -6.172 |
Valuing IsoPlexis Corporation
| Price Book Value Ratio | 0.941 | Price To Book Ratio | 0.941 |
| Price To Sales Ratio | 3.725 | Price Earnings Ratio | -0.603 |
How liquid is IsoPlexis Corporation
| Current Ratio | 10.204 |
| Quick Ratio | 6.593 |
Debt
| Debt Ratio | 0.408 | Debt Equity Ratio | 0.689 |
| Long Term Debt To Capitalization | 0.360 | Total Debt To Capitalization | 0.000 |
Latest news about IsoPlexis Corporation
BRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
IsoPlexis Corporation (NASDAQ:ISO ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Carrie Mendivil - IR Sean Mackay - CEO John Strahley - CFO Conference Call Participants Vijay Kumar - Evercore Max Masucci - Cowen Puneet Souda - SVB Leerink Tejas Savant - Morgan Stanley Operator Good morning ladies and gentlemen, thank you for standing by. And welcome to IsoPlexis' Second Quarter 2022 Earnings Conference Call.
BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
IsoLight and Duomic Technologies Detect T Cell Receptors and Highly Multiplexed Functional Cytokines from the Same Single Cells to Advance Cancer Immunology Discovery IsoLight and Duomic Technologies Detect T Cell Receptors and Highly Multiplexed Functional Cytokines from the Same Single Cells to Advance Cancer Immunology Discovery
IsoPlexis' (ISO) CEO Sean Mackay on Q4 2021 Results - Earnings Call Transcript
About IsoPlexis Corporation
Description :
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
